Literature DB >> 10357007

Increasing plasma fibrinogen, but unchanged levels of intraplatelet cyclic nucleotides, plasma endothelin-1, factor VII, and neopterin during cholesterol lowering with fluvastatin.

A Gottsäter1, I Anwaar, P Lind, I Mattiasson, F Lindgärde.   

Abstract

Lipid-lowering statin treatment reduces cardiovascular morbidity and mortality and improves endothelial function in patients with hypercholesterolemia. The aim of the present study was to evaluate plasma levels of fibrinogen, factor VII, and the macrophage-derived inflammatory mediator neopterin during lipid lowering. In addition, the endothelial production of platelet antiaggregatory and vasodilatory factors such as nitric oxide and prostacyclin, and vasoconstrictive factors such as endothelin-1, was assessed. Plasma fibrinogen, factor VII, endothelin-1, and the neopterin and intraplatelet nitric oxide and prostacyclin mediators cyclic 3'-5'guanosine monophosphate (cGMP) and cyclic 3'-5'adenosine monophosphate (cAMP) were measured before and 6 months after the institution of treatment with fluvastatin in 17 patients (eight men and nine women, median age 60 years) with vascular disease and previously untreated hypercholesterolemia. After 6 months, a decrease of 1.62 mmol/l [1.26-2.18 (19%); P < 0.01] was noted in levels of total cholesterol, and a decrease of 1.70 mmol/l [1.52-2.30 (28%); P < 0.01] in levels of low-density lipoprotein cholesterol. Plasma levels of fibrinogen had increased [from 4.81 g/l (4.26-5.27) to 5.17 g/l (4.81-5.67); P < 0.05], whereas no significant changes had occurred in intraplatelet levels of cGMP [decrease by 0.05 pmol/10(9) platelets (-0.17 to 0.24); NS], cAMP [decrease by 0.13 pmol/10(9) platelets (-0.37 to 0.86); NS], plasma endothelin-1 [decrease by 0.05 pg/ml (-0.60 to 0.70); NS], plasma factor VII [from 1.14 IE/ml (0.58-1.38) to 1.22 IE/ml (0.96-1.46); NS], or plasma neopterin [from 8.6 nmol/l (7.1-11.5) to 8.7 nmol/l (7.9-11.3); NS]. In conclusion, during cholesterol-lowering treatment with fluvastatin, plasma levels of fibrinogen increased whereas intraplatelet cyclic nucleotide levels and plasma endothelin-1, factor VII and neopterin levels were unchanged.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10357007     DOI: 10.1097/00001721-199904000-00004

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  6 in total

Review 1.  [Non-lipid effects of statins: myth or fact?].

Authors:  Eleonora Urbauer; Christian Joukhadar
Journal:  Wien Med Wochenschr       Date:  2003

Review 2.  Pleiotropic effects of statins.

Authors:  J A Farmer
Journal:  Curr Atheroscler Rep       Date:  2000-05       Impact factor: 5.113

Review 3.  Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes.

Authors:  Robert Krysiak; Boguslaw Okopień; Zbigniew Herman
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 4.  Fluvastatin for lowering lipids.

Authors:  Stephen P Adams; Sarpreet S Sekhon; Michael Tsang; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2018-03-06

5.  Differential effect of statin use on coagulation markers: an active comparative analysis in the NEO study.

Authors:  Mohammadreza Bordbar; Renée de Mutsert; Melike Cevval; Frits R Rosendaal; J Wouter Jukema; Willem M Lijfering
Journal:  Thromb J       Date:  2021-06-27

Review 6.  Analysis of antihypertensive effects of statins.

Authors:  Haralampos J Milionis; Evagelos N Liberopoulos; Moses S Elisaf; Dimitri P Mikhailidis
Journal:  Curr Hypertens Rep       Date:  2007-06       Impact factor: 4.592

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.